Developer docs
API playgroundTry for free, no card

Search company profiles

Intralytix

Full company profile

uuid0002scn

Namestring
Intralytix
Legal namestring
Intralytix, Inc.
Websiteurl
intralytix.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Intralytix is a privately held biotechnology company founded in 1998 in Baltimore (now headquartered in Columbia, Maryland) that develops, manufactures, and commercializes bacteriophage-based products for food safety, pet food safety, dietary supplements, and human therapeutics. Its technology uses naturally occurring lytic bacteriophages to selectively target and kill specific pathogenic bacteria such as Listeria monocytogenes, Salmonella, Shiga toxin-producing E. coli (STEC), Shigella, and Campylobacter in food processing environments, as well as to modulate the human microbiome for gut, oral, skin, and urinary tract health. The company holds the world's largest portfolio of FDA- and USDA-approved phage products — five food safety products plus the first FDA CVM-approved pet food phage (SalmoLyze) — and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage products under 21 CFR 117, supported by the only SQF certification in the phage industry. Three Phase 1/2a clinical trials (EcoActive for Crohn's disease, ShigActive for dysentery, VRELysin for VRE) target human therapeutic applications.

Intralytix generates revenue through direct sales of approved phage products to food processing companies, pet food manufacturers, and nutraceutical brands (via its sales@intralytix.com channel and 1-877-ITX-PHAGE line), supplemented by licensing/partnership agreements (e.g., Life Extension for VMS products) and grant funding (NIH P01, Maryland Manufacturing 4.0). Product development is powered by two proprietary AI/robotics platforms — PhageSelector for optimal phage cocktail design and PhageEngine for scaling phage-host growth dynamics to commercial cGMP production. The company achieved profitability in 2024, an uncommon milestone in the phage industry, following 800% cumulative growth in food safety product sales over 7-8 years and 76% YoY revenue growth from 2023 to 2024.

The customer base is concentrated in food processing verticals (ready-to-eat meats, poultry, seafood, produce, dairy), with secondary segments in pet food manufacturing, dietary supplement brands, and clinical research institutions. Go-to-market is enterprise field sales-led with technical application support, complemented by industry conference presence (Viruses of Microbes, ASM, Microbiome R&D Forums) and scientific publication-driven thought leadership. Geographic markets are currently limited to the United States, Canada, and Israel. Recent strategic moves include partnerships expanding into nutraceuticals (Life Extension, October 2025) and agriculture (Plaza Feed, December 2025), the FDA CVM approval for SalmoLyze (September 2025), and multimillion-dollar grant funding from NIH (June 2026) and the Maryland Department of Commerce (February 2026) to advance phage therapy and AI-driven manufacturing.

Short descriptiontext

Intralytix is a Columbia, Maryland-based biotechnology company founded in 1998 that develops and commercializes bacteriophage-based products for food safety, pet food, nutraceutical, and clinical therapeutic applications, holding the world's largest portfolio of FDA/USDA-approved phage products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersColumbia, United States
HQ citystring
Columbia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bacteriophage products, food safety biocontrol, phage-based therapeutics, pathogen control solutions, microbial biotechnology
Industry3 codes
PRIMARYAFAJAFAG
Bacteriocins & Biopreservatives (Nisin, Natamycin, Pediocin)
Agriculture & Food Production/Food Ingredients & Additives/Preservatives & Antimicrobials (Organic Acids, Nitrates, Cultured Dextrose)
SECONDARYCRADAOAF
Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose)
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Food Manufacturing311
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Bacteriophage-based food safety and biocontrol products
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales
TypeOne Time License
Description

Direct sales of FDA/USDA-approved bacteriophage products for food safety applications including ListShield™, SalmoFresh™, EcoShield™ PX, ShigaShield™, CampyShield™. Also pet food safety products and dietary supplements.

intralytix.com
2Partnership Agreements
TypeLicensing Royalties
Description

Revenue from industry partnership agreements including collaborations with Life Extension for VMS products and other commercial partnerships.

intralytix.com
3Grant Funding
TypeSubscription Recurring
Description

NIH grants (multimillion-dollar P01 grant for phage therapy research), Maryland Manufacturing 4.0 grants for AI-ML driven phage manufacturing development.

openpr.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1ListShield
Description

FDA-approved bacteriophage product targeting Listeria monocytogenes contamination in foods and food processing facilities

intralytix.com
+10 more records
Core offering1 text field

Intralytix discovers, manufactures, and markets bacteriophage-based biological products that selectively kill targeted bacterial pathogens in food, pet food, environmental, nutraceutical, and human therapeutic applications. The company holds the world's largest portfolio of FDA- and USDA-approved phage products and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage preparations. Revenue is driven by direct sales of approved biocontrol products (food safety, pet food) and the advancement of clinical-stage phage therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99-99.9% reduction in targeted bacteria in foods
+3 more records
Product overview1 text field

Intralytix offers the world's largest portfolio of FDA- and USDA-approved bacteriophage-based products across three main segments: Food Safety (ListShield™, SalmoFresh™, EcoShield™ PX, ShigaShield™, CampyShield™), Pet Food Safety (SalmoLyze®, PetShield, ListPhage™, Ecolicide®, Ecolicide® PX), and Dietary Supplements/Nutraceuticals (FortiPhage™, PhageBiotix™ GI, PhageBiotix™ UTS, PhageBiotix™ TRiP, SuperBiotix™ UTS, FortiPhage™ Plus, StaphLyse™). The company is also advancing Human Therapeutics with three Phase 1/2a clinical trials (EcoActive™ for Crohn's disease, ShigActive™ for Shigellosis, VRELysin™ for VRE). Product development is powered by proprietary AI platforms PhageSelector™ and PhageEngine™ for cocktail optimization and manufacturing scale-up.

Product and service22 records
1ListShield™
CategoryFood safety - Listeria control
Description

FDA- and USDA-approved bacteriophage preparation targeting Listeria monocytogenes contamination in foods and food processing facilities. First phage product to receive FDA approval worldwide. GRAS affirmed (GRN 528) for direct application to meat, poultry, fish, shellfish, fruits, vegetables, and dairy products, and listed under FSIS Directive 7120.1 as a safe and suitable processing aid.

2SalmoFresh™
CategoryFood safety - Salmonella control
Description

FDA-cleared bacteriophage preparation targeting Salmonella enterica contamination in foods and food processing facilities. Targets multiple pathogenic serotypes including Typhimurium, Enteritidis, Heidelberg, Newport, Hadar, Kentucky, and others. GRAS affirmed (GRN 435) for poultry, fish, shellfish, fruits, vegetables, and other applications.

3EcoShield™ PX
CategoryFood safety - STEC E. coli control
Description

FDA-cleared bacteriophage preparation targeting Shiga toxin-producing Escherichia coli (STEC), including O157:H7 and all 'big six' STEC serotypes. FDA GRAS affirmed (GRN 834) and FCN 1018 for red meat processing; FSIS-listed as safe and suitable processing aid.

4ShigaShield™
CategoryFood safety - Shigella control
Description

Bacteriophage preparation targeting Shigella species contamination in foods and food processing facilities. FDA GRN 672 approved for direct application to foods.

5CampyShield™
CategoryFood safety - Campylobacter control
Description

Bacteriophage preparation targeting Campylobacter species and Campylobacter jejuni in foods and food processing facilities. FDA GRN 966 approved.

6SalmoLyze®
CategoryPet food safety - Salmonella control
Description

FDA CVM-approved Salmonella-specific bacteriophage preparation for use as a processing aid to control Salmonella enterica in pet food and pet food ingredients. First phage product authorized by FDA CVM for pet food applications.

7PetShield
CategoryPet food safety - multi-pathogen control
Description

Bacteriophage preparation targeting Shiga-toxin producing E. coli (STEC), Salmonella, and Listeria monocytogenes contamination in pet food.

8ListPhage™
CategoryPet food safety - Listeria control
Description

Bacteriophage preparation targeting Listeria monocytogenes contamination in pet food.

9Ecolicide®
CategoryPet food safety - E. coli O157:H7 control
Description

Bacteriophage preparation targeting Escherichia coli O157:H7 contamination in pet food.

10Ecolicide® PX
CategoryPre-harvest intervention - E. coli O157:H7 control
Description

Pre-harvest intervention bacteriophage preparation targeting Escherichia coli O157:H7 contamination on hides of live animals.

11PhageBiotix™ FOP
CategoryFood safety - multi-pathogen cocktail
Description

Complex phage preparation containing 9 to 15 lytic bacteriophages targeting L. monocytogenes, Salmonella spp., and Shiga-toxin producing E. coli (STEC) for food safety applications.

12FortiPhage™
CategoryNutraceutical - gut health
Description

Dietary supplement composed of three Myoviridae bacteriophages designed to maintain healthy gut microflora. Non-GMO, 100% natural product supporting daily digestive health and replenishing phages in the GI tract.

13PhageBiotix™ GI
CategoryNutraceutical - gut health
Description

Advanced bacteriophage blend formulated for enhanced support of healthy gut microflora. Part of the patented PhageBiotix™ platform for microbiome modulation.

14PhageBiotix™ UTS
CategoryNutraceutical - urinary tract health
Description

Bacteriophage-based product designed to help maintain healthy gut and urinary tract microflora.

15PhageBiotix™ TRiP
CategoryNutraceutical - travel digestive support
Description

Bacteriophage product formulated to support healthy gut microflora during travel.

16SuperBiotix™ UTS
CategoryNutraceutical - probiotic + phage combination
Description

Bacteriophage-based dietary supplement combining traditional probiotic cultures with PhageBiotix™ phage preparations to maintain healthy gut and urinary tract microflora.

17FortiPhage™ Plus
CategoryNutraceutical - probiotic + phage combination
Description

Bacteriophage-based product combining FortiPhage™ with probiotics for enhanced gut microflora support.

18StaphLyse™
CategoryNutraceutical - skin and microflora support
Description

Bacteriophage product designed to support healthy microflora; also available as part of skin care program Revitalyse®.

19EcoActive™
CategoryClinical-stage human therapeutic - Crohn's disease / AIEC
Description

Bacteriophage therapy targeting adherent-invasive E. coli (AIEC) in Crohn's disease patients. Currently in Phase 1/2a clinical trial at Mount Sinai Hospital and Johns Hopkins University. ClinicalTrials.gov NCT03808103.

20ShigActive™
CategoryClinical-stage human therapeutic - Shigella dysentery
Description

Bacteriophage therapy targeting Shigella for treating dysentery. Phase 1/2a clinical trial at University of Maryland Center for Vaccine Development. ClinicalTrials.gov NCT05182749.

21VRELysin™
CategoryClinical-stage human therapeutic - vancomycin-resistant Enterococci (VRE)
Description

Bacteriophage therapy targeting vancomycin-resistant Enterococci colonization in the gastrointestinal tract. Phase 1/2a clinical trial at UPMC Pittsburgh. ClinicalTrials.gov NCT05715619.

22Life Extension Phage-based Nutraceutical
CategoryNutraceutical - VMS co-development
Description

Co-developed phage-based nutraceutical with Life Extension for the vitamins, minerals, and supplements (VMS) market, expanding bacteriophage technology into evidence-based health and wellness formulations.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

NIH P01 grant partnership through Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). Joint initiative to develop phage therapy for multidrug-resistant Pseudomonas aeruginosa infections. Co-PI Dr. Alexander Sulakvelidze from Intralytix with collaborators from University of Pittsburgh, Walter Reed Army Institute of Research, USC, and Florida International University.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Collaboration on a new bacteriophage kit for agricultural and microbiological applications. Focus on developing phage-based solutions for the agricultural sector.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Collaboration to co-develop and commercialize a leading-edge phage-based nutraceutical for the vitamins, minerals, and supplements (VMS) sector. Aims to expand the role of bacteriophage technology within the health and wellness market, establishing a framework for evidence-based, phage-powered nutraceutical formulations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intralytix

Bacteriophage-based food safety and biocontrol productsintralytix.com

Intralytix is a Columbia, Maryland-based biotechnology company founded in 1998 that develops and commercializes bacteriophage-based products for food safety, pet food, nutraceutical, and clinical therapeutic applications, holding the world's largest portfolio of FDA/USDA-approved phage products.

What Intralytix does

Intralytix is a privately held biotechnology company founded in 1998 in Baltimore (now headquartered in Columbia, Maryland) that develops, manufactures, and commercializes bacteriophage-based products for food safety, pet food safety, dietary supplements, and human therapeutics. Its technology uses naturally occurring lytic bacteriophages to selectively target and kill specific pathogenic bacteria such as Listeria monocytogenes, Salmonella, Shiga toxin-producing E. coli (STEC), Shigella, and Campylobacter in food processing environments, as well as to modulate the human microbiome for gut, oral, skin, and urinary tract health. The company holds the world's largest portfolio of FDA- and USDA-approved phage products — five food safety products plus the first FDA CVM-approved pet food phage (SalmoLyze) — and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage products under 21 CFR 117, supported by the only SQF certification in the phage industry. Three Phase 1/2a clinical trials (EcoActive for Crohn's disease, ShigActive for dysentery, VRELysin for VRE) target human therapeutic applications.

Intralytix generates revenue through direct sales of approved phage products to food processing companies, pet food manufacturers, and nutraceutical brands (via its sales@intralytix.com channel and 1-877-ITX-PHAGE line), supplemented by licensing/partnership agreements (e.g., Life Extension for VMS products) and grant funding (NIH P01, Maryland Manufacturing 4.0). Product development is powered by two proprietary AI/robotics platforms — PhageSelector for optimal phage cocktail design and PhageEngine for scaling phage-host growth dynamics to commercial cGMP production. The company achieved profitability in 2024, an uncommon milestone in the phage industry, following 800% cumulative growth in food safety product sales over 7-8 years and 76% YoY revenue growth from 2023 to 2024.

The customer base is concentrated in food processing verticals (ready-to-eat meats, poultry, seafood, produce, dairy), with secondary segments in pet food manufacturing, dietary supplement brands, and clinical research institutions. Go-to-market is enterprise field sales-led with technical application support, complemented by industry conference presence (Viruses of Microbes, ASM, Microbiome R&D Forums) and scientific publication-driven thought leadership. Geographic markets are currently limited to the United States, Canada, and Israel. Recent strategic moves include partnerships expanding into nutraceuticals (Life Extension, October 2025) and agriculture (Plaza Feed, December 2025), the FDA CVM approval for SalmoLyze (September 2025), and multimillion-dollar grant funding from NIH (June 2026) and the Maryland Department of Commerce (February 2026) to advance phage therapy and AI-driven manufacturing.

Intralytix firmographics

Firmographics
Name
Intralytix
Legal name
Intralytix, Inc.
Website
https://intralytix.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Short description
Intralytix is a Columbia, Maryland-based biotechnology company founded in 1998 that develops and commercializes bacteriophage-based products for food safety, pet food, nutraceutical, and clinical therapeutic applications, holding the world's largest portfolio of FDA/USDA-approved phage products.
Ownership category
akta.pro rank

Intralytix industry classification

Industry
Product category
Bacteriophage-based food safety and biocontrol products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Food Manufacturing (311), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYAFAJAFAG
Bacteriocins & Biopreservatives (Nisin, Natamycin, Pediocin)
Agriculture & Food Production/Food Ingredients & Additives/Preservatives & Antimicrobials (Organic Acids, Nitrates, Cultured Dextrose)
SECONDARYCRADAOAF
Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose)
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Bacteriophage products
  • Food safety biocontrol
  • Phage-based therapeutics
  • Pathogen control solutions
  • Microbial biotechnology

Where Intralytix is headquartered

Location

Headquarters

HQ city
Columbia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Intralytix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

  1. Product Sales: Direct sales of FDA/USDA-approved bacteriophage products for food safety applications including ListShield™, SalmoFresh™, EcoShield™ PX, ShigaShield™, CampyShield™. Also pet food safety products and dietary supplements.
  2. Partnership Agreements: Revenue from industry partnership agreements including collaborations with Life Extension for VMS products and other commercial partnerships.
  3. Grant Funding: NIH grants (multimillion-dollar P01 grant for phage therapy research), Maryland Manufacturing 4.0 grants for AI-ML driven phage manufacturing development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Intralytix product offering

Product offering

Core offering

Intralytix discovers, manufactures, and markets bacteriophage-based biological products that selectively kill targeted bacterial pathogens in food, pet food, environmental, nutraceutical, and human therapeutic applications. The company holds the world's largest portfolio of FDA- and USDA-approved phage products and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage preparations. Revenue is driven by direct sales of approved biocontrol products (food safety, pet food) and the advancement of clinical-stage phage therapies.

Product overview

Intralytix offers the world's largest portfolio of FDA- and USDA-approved bacteriophage-based products across three main segments: Food Safety (ListShield™, SalmoFresh™, EcoShield™ PX, ShigaShield™, CampyShield™), Pet Food Safety (SalmoLyze®, PetShield, ListPhage™, Ecolicide®, Ecolicide® PX), and Dietary Supplements/Nutraceuticals (FortiPhage™, PhageBiotix™ GI, PhageBiotix™ UTS, PhageBiotix™ TRiP, SuperBiotix™ UTS, FortiPhage™ Plus, StaphLyse™). The company is also advancing Human Therapeutics with three Phase 1/2a clinical trials (EcoActive™ for Crohn's disease, ShigActive™ for Shigellosis, VRELysin™ for VRE). Product development is powered by proprietary AI platforms PhageSelector™ and PhageEngine™ for cocktail optimization and manufacturing scale-up.

Differentiator

Problem solved

Functional benefit

Brands

  • ListShield: FDA-approved bacteriophage product targeting Listeria monocytogenes contamination in foods and food processing facilities
  • SalmoFresh
  • EcoShield
  • PhageBiotix
  • SuperBiotix
  • PhageEngine
  • PhageSelector
  • SalmoLyze
  • EcoActive
  • ShigActive
  • VRELysin

Products and services

  • ListShield™ FDA- and USDA-approved bacteriophage preparation targeting Listeria monocytogenes contamination in foods and food processing facilities. First phage product to receive FDA approval worldwide. GRAS affirmed (GRN 528) for direct application to meat, poultry, fish, shellfish, fruits, vegetables, and dairy products, and listed under FSIS Directive 7120.1 as a safe and suitable processing aid.
  • SalmoFresh™ FDA-cleared bacteriophage preparation targeting Salmonella enterica contamination in foods and food processing facilities. Targets multiple pathogenic serotypes including Typhimurium, Enteritidis, Heidelberg, Newport, Hadar, Kentucky, and others. GRAS affirmed (GRN 435) for poultry, fish, shellfish, fruits, vegetables, and other applications.
  • EcoShield™ PX FDA-cleared bacteriophage preparation targeting Shiga toxin-producing Escherichia coli (STEC), including O157:H7 and all 'big six' STEC serotypes. FDA GRAS affirmed (GRN 834) and FCN 1018 for red meat processing; FSIS-listed as safe and suitable processing aid.
  • ShigaShield™ Bacteriophage preparation targeting Shigella species contamination in foods and food processing facilities. FDA GRN 672 approved for direct application to foods.
  • CampyShield™ Bacteriophage preparation targeting Campylobacter species and Campylobacter jejuni in foods and food processing facilities. FDA GRN 966 approved.
  • SalmoLyze® FDA CVM-approved Salmonella-specific bacteriophage preparation for use as a processing aid to control Salmonella enterica in pet food and pet food ingredients. First phage product authorized by FDA CVM for pet food applications.
  • PetShield Bacteriophage preparation targeting Shiga-toxin producing E. coli (STEC), Salmonella, and Listeria monocytogenes contamination in pet food.
  • ListPhage™ Bacteriophage preparation targeting Listeria monocytogenes contamination in pet food.
  • Ecolicide® Bacteriophage preparation targeting Escherichia coli O157:H7 contamination in pet food.
  • Ecolicide® PX Pre-harvest intervention bacteriophage preparation targeting Escherichia coli O157:H7 contamination on hides of live animals.
  • PhageBiotix™ FOP Complex phage preparation containing 9 to 15 lytic bacteriophages targeting L. monocytogenes, Salmonella spp., and Shiga-toxin producing E. coli (STEC) for food safety applications.
  • FortiPhage™ Dietary supplement composed of three Myoviridae bacteriophages designed to maintain healthy gut microflora. Non-GMO, 100% natural product supporting daily digestive health and replenishing phages in the GI tract.
  • PhageBiotix™ GI Advanced bacteriophage blend formulated for enhanced support of healthy gut microflora. Part of the patented PhageBiotix™ platform for microbiome modulation.
  • PhageBiotix™ UTS Bacteriophage-based product designed to help maintain healthy gut and urinary tract microflora.
  • PhageBiotix™ TRiP Bacteriophage product formulated to support healthy gut microflora during travel.
  • SuperBiotix™ UTS Bacteriophage-based dietary supplement combining traditional probiotic cultures with PhageBiotix™ phage preparations to maintain healthy gut and urinary tract microflora.
  • FortiPhage™ Plus Bacteriophage-based product combining FortiPhage™ with probiotics for enhanced gut microflora support.
  • StaphLyse™ Bacteriophage product designed to support healthy microflora; also available as part of skin care program Revitalyse®.
  • EcoActive™ Bacteriophage therapy targeting adherent-invasive E. coli (AIEC) in Crohn's disease patients. Currently in Phase 1/2a clinical trial at Mount Sinai Hospital and Johns Hopkins University. ClinicalTrials.gov NCT03808103.
  • ShigActive™ Bacteriophage therapy targeting Shigella for treating dysentery. Phase 1/2a clinical trial at University of Maryland Center for Vaccine Development. ClinicalTrials.gov NCT05182749.
  • VRELysin™ Bacteriophage therapy targeting vancomycin-resistant Enterococci colonization in the gastrointestinal tract. Phase 1/2a clinical trial at UPMC Pittsburgh. ClinicalTrials.gov NCT05715619.
  • Life Extension Phage-based Nutraceutical Co-developed phage-based nutraceutical with Life Extension for the vitamins, minerals, and supplements (VMS) market, expanding bacteriophage technology into evidence-based health and wellness formulations.

Quantifiable outcome

  • 99-99.9% reduction in targeted bacteria in foods
  • +3 more outcomes

Companies that use Intralytix

Customer profile

Segments4 records

Ideal customer profiles4 records

Intralytix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Intralytix partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • University of PittsburghcoreStrategic or Co-development Partner · 1 June 2026NIH P01 grant partnership through Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). Joint initiative to develop phage therapy for multidrug-resistant Pseudomonas aeruginosa infections. Co-PI Dr. Alexander Sulakvelidze from Intralytix with collaborators from University of Pittsburgh, Walter Reed Army Institute of Research, USC, and Florida International University.
  • Plaza Feed & Crop NutritioncoreStrategic or Co-development Partner · 11 December 2025Collaboration on a new bacteriophage kit for agricultural and microbiological applications. Focus on developing phage-based solutions for the agricultural sector.
  • Life ExtensioncoreStrategic or Co-development Partner · 1 October 2025Collaboration to co-develop and commercialize a leading-edge phage-based nutraceutical for the vitamins, minerals, and supplements (VMS) sector. Aims to expand the role of bacteriophage technology within the health and wellness market, establishing a framework for evidence-based, phage-powered nutraceutical formulations.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Intralytix competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Intralytix social profiles

Digital presence

Intralytix compliance and trust

Trust signal

Compliance11 records

Intralytix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intralytix leadership team

Management profile

Number of profiles

Profiles9 records

Intralytix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intralytix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intralytix

What does Intralytix do?

Intralytix discovers, manufactures, and markets bacteriophage-based biological products that selectively kill targeted bacterial pathogens in food, pet food, environmental, nutraceutical, and human therapeutic applications. The company holds the world's largest portfolio of FDA- and USDA-approved phage products and operates the largest U.S. cGMP manufacturing capacity for FDA-approved bacteriophage preparations. Revenue is driven by direct sales of approved biocontrol products (food safety, pet food) and the advancement of clinical-stage phage therapies.

Is Intralytix a public or private company?

Intralytix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Intralytix founded?

Intralytix was founded in 1998. It employs 11 to 50 people.

Where is Intralytix based?

Intralytix is headquartered in Columbia, United States, in the North America region.

How does Intralytix make money?

Three revenue lines are on record. Product Sales are the primary driver. The others are partnership Agreements and grant Funding.

Does Intralytix have an API?

No public API is recorded for Intralytix.

What industry is Intralytix in?

Intralytix's product category is Bacteriophage-based food safety and biocontrol products. Its primary akta.pro industry code is AFAJAFAG, Bacteriocins & Biopreservatives (Nisin, Natamycin, Pediocin), with a secondary code of CRADAOAF, Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarylandMaryland awards $2 million for Industry 4.0 technologiesMaryland's Manufacturing 4.0 grant program has awarded $2 million to 22 small and mid-sized manufacturing companies across 10 jurisdictions to invest in Industry 4.0 technologies, supporting more than 1,100 jobs in the state. The funded projects include automated batching and robotic systems at Michele's Granola and an AI computing system at Intralytix, Inc. for phage production optimization. The governor's proposed fiscal year 2027 budget includes an additional $2 million for the program.IntralytixIntralytix Receives FDA CVM Approval for <i>Salmonella</i>-Targeting Phage Preparation for Use in Pet Food ApplicationsIntralytix received FDA CVM approval for its Salmonella-specific bacteriophage preparation, SalmoLyze™, to be used as a processing aid in pet food and ingredients. This marks the first authorization of a bacteriophage product by the CVM for reducing Salmonella contamination in this sector. The approval validates the safety and effectiveness of phage-based interventions for improving food safety standards.IntralytixAB Agri has partnered with US biotechnology company Intralytix to explore the use of bacteriophages – the natural viruses of bacteria – in animal feed as an alternative to antibiotics and other drugsAB Agri has partnered with US biotechnology company Intralytix to explore using bacteriophages as an antibiotic alternative in animal feed. This collaboration builds on previous research demonstrating that bacteriophages can effectively reduce pathogenic bacteria levels in broiler chickens.PR NewswireBenchmark of the Top 10 Microbiome Therapeutics Companies 2020: 4D Pharma, ENTEROME, Finch, Intralytix, Locus Biosciences, Microbiotica, Second Genome, Seres Therapeutics, Rebiotix, Vedanta BioscienceResearchAndMarkets.com has published a benchmark report profiling the top 10 companies actively developing microbiome therapeutics, covering firms such as 4D Pharma, ENTEROME, Finch Therapeutics, Intralytix, Locus Biosciences, Microbiotica, Second Genome, Seres Therapeutics, Rebiotix (Ferring Pharmaceuticals), and Vedanta Biosciences.PR NewswireIntralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in HumansIntralytix, Inc. received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, to fund clinical development of its bacteriophage therapy preparation for treating Shigella infections in humans. The funding will support Phase 1/2a clinical trials to assess the safety and efficacy of the treatment, with the goal of addressing a pathogen that affects approximately 125 million people worldwide annually and causes roughly 14,000 deaths, predominantly in young children. The award is expected to help establish bacteriophage therapy as a complementary approach to existing anti-infectives and potentially pave the way for therapies against other bacterial pathogens including cholera.PR NewswireIntralytix Receives FDA Clearance to Initiate Phase I / IIa Clinical TrialsIntralytix, Inc. received FDA clearance to initiate Phase I/IIa clinical trials at Mount Sinai hospital in New York for a bacteriophage therapy targeting adhesive invasive E. coli (AIEC) associated with Crohn's disease and inflammatory bowel disease. The company entered into a collaboration with Ferring Pharmaceuticals in July 2015 to develop this proprietary phage preparation, marking one of the first INDs approved for bacteriophages by the FDA and the first-ever IND approved for targeting AIEC in patients. Dr. Jean-Frederic Colombel from the Icahn School of Medicine at Mount Sinai will serve as Principal Investigator for the trial.PR NewswireLesaffre Invests in Intralytix, a US Biotechnology CompanyIntralytix announced it received $17.5 million in new equity funding from Lesaffre, a French family group, marking the beginning of a collaboration to develop and commercialize bacteriophage-based products for human health and other areas. The investment will enable Intralytix to strengthen its R&D programs, add high throughput robotic technologies, and expand its phage production capabilities. Both companies aim to develop antimicrobial products using bacteriophage technology to help reduce antibiotic resistance and benefit customers worldwide.PR NewswireIntralytix Receives FDA Regulatory Clearance for Phage-Based Shigella TechnologyIntralytix announced that its phage-based food safety product ShigaShield™ has received GRAS (Generally Recognized As Safe) recognition from the FDA. The product uses naturally occurring lytic bacteriophages to selectively control Shigella species, a major foodborne and waterborne pathogen estimated to cause 80-165 million cases annually worldwide and over 500,000 cases in the United States annually. The company highlighted potential applications for improving food safety for the US military and travelers in regions with suboptimal sanitation standards.